Cargando…

Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes

INTRODUCTION: We evaluated the effectiveness of long-term continuous subcutaneous insulin infusion (CSII) compared with multiple daily insulin (MDI) injections for glycaemic control and variability, hypoglycaemic episodes and maternal/neonatal outcomes in pregnant women with pre-existing type 1 diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Jotic, Aleksandra, Milicic, Tanja, Lalic, Katarina, Lukic, Ljiljana, Macesic, Marija, Stanarcic Gajovic, Jelena, Stoiljkovic, Milica, Gojnic Dugalic, Miroslava, Jeremic, Veljko, Lalic, Nebojsa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136374/
https://www.ncbi.nlm.nih.gov/pubmed/32060738
http://dx.doi.org/10.1007/s13300-020-00780-7
_version_ 1783518234270498816
author Jotic, Aleksandra
Milicic, Tanja
Lalic, Katarina
Lukic, Ljiljana
Macesic, Marija
Stanarcic Gajovic, Jelena
Stoiljkovic, Milica
Gojnic Dugalic, Miroslava
Jeremic, Veljko
Lalic, Nebojsa M.
author_facet Jotic, Aleksandra
Milicic, Tanja
Lalic, Katarina
Lukic, Ljiljana
Macesic, Marija
Stanarcic Gajovic, Jelena
Stoiljkovic, Milica
Gojnic Dugalic, Miroslava
Jeremic, Veljko
Lalic, Nebojsa M.
author_sort Jotic, Aleksandra
collection PubMed
description INTRODUCTION: We evaluated the effectiveness of long-term continuous subcutaneous insulin infusion (CSII) compared with multiple daily insulin (MDI) injections for glycaemic control and variability, hypoglycaemic episodes and maternal/neonatal outcomes in pregnant women with pre-existing type 1 diabetes (pT1D). METHODS: Our observational cohort study included 128 consecutive pregnant women with pT1D, who were treated from 1 January 2010 to 31 December 2017. Of 128 participants, 48 were on CSII and 80 were on MDI. Glycaemic control was determined by glycated haemoglobin (HbA1c) (captured in preconception and each trimester of pregnancy). Glucose variability (GV) was expressed as the coefficient of variation (CV) [calculated from self-monitoring of blood glucose (SMBG) values], and hypoglycaemia was defined as glucose values < 3.9 mmol/l. The data on maternal and neonatal outcomes were collected from obstetrical records. RESULTS: Duration of the treatment was 8.8 ± 5.3 years in the CSII and 12.6 ± 8.0 years in the MDI group. The CSII lowered HbA1c in preconception (7.1 ± 0.1 vs. 7.9 ± 0.2%, p = 0.03) and the first (6.9 ± 0.1 vs. 7.7 ± 0.2%, p = 0.02), second (6.6 ± 0.1 vs. 7.2 ± 0.1%, p = 0.003) and third (6.5 ± 0.1 vs. 6.8 ± 0.1%, p = 0.02) trimesters significantly better than MDI. Significantly lower CV was observed only for fasting glycaemia in the first trimester (17.1 vs 28.4%, p < 0.001) in favour of CSII. Moreover, the CSII group had significantly lower mean hypoglycaemic episodes/week/patient only during the first trimester (2.0 ± 1.7 vs 4.8 ± 1.5, p < 0.01). In early pregnancy, the majority of women on CSII had less hypoglycaemia than on MDI (0–3: 79.1 vs. 29.1%; 4–6: 18.8 vs. 65.8%; ≥ 7: 2.1 vs. 5.1%, p < 0.01, respectively). We found no difference in the incidence of adverse maternal/neonatal outcomes. CONCLUSIONS: Treatment with CSII resulted in a favourable reduction of HbA1c in the preconception period and each trimester in pregnancy. Moreover, long-term CSII treatment demonstrated more stable metabolic control with less GV of fasting glycaemia and fewer hypoglyacemic episodes only during early pregnancy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-020-00780-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7136374
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-71363742020-04-09 Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes Jotic, Aleksandra Milicic, Tanja Lalic, Katarina Lukic, Ljiljana Macesic, Marija Stanarcic Gajovic, Jelena Stoiljkovic, Milica Gojnic Dugalic, Miroslava Jeremic, Veljko Lalic, Nebojsa M. Diabetes Ther Original Research INTRODUCTION: We evaluated the effectiveness of long-term continuous subcutaneous insulin infusion (CSII) compared with multiple daily insulin (MDI) injections for glycaemic control and variability, hypoglycaemic episodes and maternal/neonatal outcomes in pregnant women with pre-existing type 1 diabetes (pT1D). METHODS: Our observational cohort study included 128 consecutive pregnant women with pT1D, who were treated from 1 January 2010 to 31 December 2017. Of 128 participants, 48 were on CSII and 80 were on MDI. Glycaemic control was determined by glycated haemoglobin (HbA1c) (captured in preconception and each trimester of pregnancy). Glucose variability (GV) was expressed as the coefficient of variation (CV) [calculated from self-monitoring of blood glucose (SMBG) values], and hypoglycaemia was defined as glucose values < 3.9 mmol/l. The data on maternal and neonatal outcomes were collected from obstetrical records. RESULTS: Duration of the treatment was 8.8 ± 5.3 years in the CSII and 12.6 ± 8.0 years in the MDI group. The CSII lowered HbA1c in preconception (7.1 ± 0.1 vs. 7.9 ± 0.2%, p = 0.03) and the first (6.9 ± 0.1 vs. 7.7 ± 0.2%, p = 0.02), second (6.6 ± 0.1 vs. 7.2 ± 0.1%, p = 0.003) and third (6.5 ± 0.1 vs. 6.8 ± 0.1%, p = 0.02) trimesters significantly better than MDI. Significantly lower CV was observed only for fasting glycaemia in the first trimester (17.1 vs 28.4%, p < 0.001) in favour of CSII. Moreover, the CSII group had significantly lower mean hypoglycaemic episodes/week/patient only during the first trimester (2.0 ± 1.7 vs 4.8 ± 1.5, p < 0.01). In early pregnancy, the majority of women on CSII had less hypoglycaemia than on MDI (0–3: 79.1 vs. 29.1%; 4–6: 18.8 vs. 65.8%; ≥ 7: 2.1 vs. 5.1%, p < 0.01, respectively). We found no difference in the incidence of adverse maternal/neonatal outcomes. CONCLUSIONS: Treatment with CSII resulted in a favourable reduction of HbA1c in the preconception period and each trimester in pregnancy. Moreover, long-term CSII treatment demonstrated more stable metabolic control with less GV of fasting glycaemia and fewer hypoglyacemic episodes only during early pregnancy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-020-00780-7) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-02-15 2020-04 /pmc/articles/PMC7136374/ /pubmed/32060738 http://dx.doi.org/10.1007/s13300-020-00780-7 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Jotic, Aleksandra
Milicic, Tanja
Lalic, Katarina
Lukic, Ljiljana
Macesic, Marija
Stanarcic Gajovic, Jelena
Stoiljkovic, Milica
Gojnic Dugalic, Miroslava
Jeremic, Veljko
Lalic, Nebojsa M.
Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes
title Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes
title_full Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes
title_fullStr Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes
title_full_unstemmed Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes
title_short Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes
title_sort evaluation of glycaemic control, glucose variability and hypoglycaemia on long-term continuous subcutaneous infusion vs. multiple daily injections: observational study in pregnancies with pre-existing type 1 diabetes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136374/
https://www.ncbi.nlm.nih.gov/pubmed/32060738
http://dx.doi.org/10.1007/s13300-020-00780-7
work_keys_str_mv AT joticaleksandra evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT milicictanja evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT lalickatarina evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT lukicljiljana evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT macesicmarija evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT stanarcicgajovicjelena evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT stoiljkovicmilica evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT gojnicdugalicmiroslava evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT jeremicveljko evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes
AT lalicnebojsam evaluationofglycaemiccontrolglucosevariabilityandhypoglycaemiaonlongtermcontinuoussubcutaneousinfusionvsmultipledailyinjectionsobservationalstudyinpregnancieswithpreexistingtype1diabetes